Free Trial
NASDAQ:NLSP

NLS Pharmaceutics (NLSP) Stock Price, News & Analysis

NLS Pharmaceutics logo
$1.72 -0.01 (-0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$1.75 +0.03 (+1.74%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NLS Pharmaceutics Stock (NASDAQ:NLSP)

Key Stats

Today's Range
$1.60
$1.74
50-Day Range
$1.30
$1.73
52-Week Range
$1.30
$18.39
Volume
627,213 shs
Average Volume
1.57 million shs
Market Capitalization
$6.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Receive NLSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

NLSP Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
NLS Pharmaceutics, Kadimastem announce up to $3M equity financing
NLS Pharmaceutics announces new preclinical data for AEX-2
See More Headlines

NLSP Stock Analysis - Frequently Asked Questions

NLS Pharmaceutics' stock was trading at $2.11 at the beginning of 2025. Since then, NLSP stock has decreased by 18.2% and is now trading at $1.7250.
View the best growth stocks for 2025 here
.

NLS Pharmaceutics (NLSP) raised $20 million in an IPO on Friday, January 29th 2021. The company issued 3,600,000 shares at $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Meta Platforms (META), Immunic (IMUX), Seres Therapeutics (MCRB), NVIDIA (NVDA), Tesla (TSLA).

Company Calendar

Today
5/21/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NLSP
Employees
6
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
3,008,000
Market Cap
$6.22 million
Optionable
Not Optionable
Beta
-0.21
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:NLSP) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners